ReviewCancers2023
Treatment Costs and Social Burden of Pancreatic Cancer.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of Depression on Mortality in Patients with Pancreatic Cancer: A Systematic Review.Current oncology (Toronto, Ont.) · 2025Pooled it
- State-Level Prevalence of Obesity/overweight and Pancreatic Cancer Incidence in the United States: An Ecological Analysis Using BRFSS, CDC WONDER and ACS for the Year 2021.Journal of gastrointestinal cancer · 2026Article
- Article
- Liver Metastasis Risk and Timing in Pancreatic Cancer Patients Using Electronic Health Records.medRxiv : the preprint server for health sciences · 2025Article
- Knowledge user involvement is still uncommon in published rapid reviews-a meta-research cross-sectional study.Research synthesis methods · 2025Article
- Pancreatic cancer in the era of precision medicine: challenges, advances, and the future of therapeutic strategies.Journal of the Egyptian National Cancer Institute · 2025Review
- Surgery and neoadjuvant therapy in locally advanced pancreatic cancer: an umbrella review of survival, resection outcomes, and cost-effectiveness.Gland surgery · 2025Review
- Southeast Asia burden and trend of Gastrointestinal tract cancers from 1990 to 2021 and its prediction to 2050: findings from the Global Burden of Disease Study 2021.International journal of colorectal disease · 2025Article
- Minimally invasive techniques versus opioids in patients with unresectable pancreatic cancer: a systematic review and meta-analysis of randomised controlled trials.Translational gastroenterology and hepatology · 2025Article
- Elemene Injection Suppresses Pancreatic Cancer Progress through Regulating Cell Adhesion: A Research Based upon Network Pharmacology and Verification Test.Current medicinal chemistry · 2025Article
- Burden of digestive system neoplasms in middle-aged and elderly adults: Temporal trends and geographic disparities (1990-2021).PloS one · 2025Article
- Costs of First-Line Treatment With FOLFIRINOX, Modified FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel in Metastatic Pancreatic Ductal Adenocarcinoma.Journal of health economics and outcomes research · 2025Article
- The Paradox of Palliative Care at the End of Life: Higher Rates of Aggressive Interventions in Patients with Pancreatic Cancer.Journal of clinical medicine · 2024Article
- Determination of a cut-off COmprehensive Score for financial Toxicity (COST) for identifying cost-related treatment nonadherence and impaired health-related quality of life among Chinese patients with cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Epidemiology of pancreatic cancer: New version, new vision.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- Systemic treatment for advanced pancreatic cancer.World journal of gastrointestinal oncology · 2023Review
- HRD Score: A Promising Biomarker for Genomic Instability Evaluation for Targeted Treatments Among Pancreatic Cancer Patients.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1) Background: Pancreatic cancer is the cancer with the third-highest mortality rate, and forecasts indicate its growing share in morbidity. The basis of treatment is inpatient chemotherapy and there is a strong focus on palliative care. (2) Methods: A literature review was conducted based on the rapid review methodology in PubMed and Cochrane databases. The search was supplemented with publications from the snowball search. Qualitative assessment of included publications was performed using AMSTAR2 modified scheme. (3) Results: The review included 17 publications, of which majority concerned direct costs related to the adopted treatment regimen. Most of the publications focused on comparing the cost-effectiveness of drug therapies and the costs of palliative treatment. Other publications concerned indirect costs generated by pancreatic cancer. They particularly focused on the economic burden of lost productivity due to sickness absence. (4) Conclusion: The increase in the incidence of pancreatic cancer translates into an increase in the costs of the health care system and indirect costs. Due to the significant share of hospitalization in the health care structure, direct costs are increasing. The inpatient treatment regimen and side effects translate into a loss of productivity for patients with pancreatic cancer. Among gastrointestinal cancers, pancreatic cancer generates the second largest indirect costs, although it has a much lower incidence rate than the dominant colorectal cancer. This indicates a significant problem of the economic burden of this cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.